Table 1 The primary characteristics of the selected studies
From: Pooled safety analyses of ALK-TKI inhibitor in ALK-positive NSCLC
First author | Treatment | No. of patients | No. of treatment-related toxicities grade ≥ 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Â | Â | Â | Total | Hepatotoxicity | Neutropenia | Dyspnoea | Fatigue | Vomiting | Diarrhoea | Nausea | Constipation | Amylase increased | Elevated lipase |
D.W. Kim [10] | Crizotinib | 136 | 27 | 5 | 3 | 4 | NA | NA | NA | NA | NA | NA | NA |
Camidge, D. R. [11] | Crizotinib | 149 | 36 | 6 | 9 | 1 | 2 | 1 | 0 | 1 | 1 | 0 | 0 |
Perol, M. [12] | Crizotinib | 187 | NA | 5 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Shaw, Alice T. [13] | Crizotinib | 172 | 57 | 27 | 23 | 7 | 4 | 2 | 0 | 2 | 4 | NA | NA |
Cao, Y. [14] | Crizotinib | 40 | 6 | 4 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 |
Hernandez, Berta [15] | Crizotinib | 10 | NA | 2 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Shaw, A. T. [3] | Ceritinib | 81 | 46 | 19 | NA | NA | 5 | 5 | 6 | 6 | NA | 8 | 8 |
Solomon, B. J. [16] | Crizotinib | 171 | NA | 24 | 19 | 5 | 5 | 3 | 4 | 2 | 3 | NA | NA |
Chaigneau, A. [4] | Ceritinib | 10 | 2 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cui, S. [17] | Crizotinib | 72 | 10 | 3 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
Felip, E. [5] | Ceritinib | 124 | NA | 17 | NA | NA | NA | NA | NA | NA | NA | NA | NA |
Mok, T. [6] | Ceritinib | 140 | 64 | 22 | NA | NA | NA | 6 | 9 | 8 | NA | NA | NA |
Cui, S. [18] | Crizotinib | 56 | 8 | 2 | 0 | 0 | 0 | 5 | 0 | 0 | 0 | 0 | 0 |
Kim, D. W. [7] | Ceritinib | 246 | 125 | 73 | 0 | 10 | 12 | 11 | 15 | 15 | 0 | 8 | 16 |
Ou, Sai-Hong [8] | Alectinib | 138 | 38 | 2 | NA | 4 | 1 | 1 | 1 | 0 | 0 | NA | NA |
Shaw, A. T. [9] | Alectinib | 87 | 35 | 5 | 1 | 3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Zhang, Q. [19] | Crizotinib | 7 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |